感染症診断薬市場：製品（試薬、キット、機器、ソフトウェア）、検査タイプ（ラボ、POC）、疾患（COVID-19、インフルエンザ、HAI、HIV、HPV）、技術（免疫診断薬、NGS、INAAT、PCR）、エンドユーザー（病院、ラボ）別-2027年までの世界予測

Infectious Disease Diagnostics Market by Product (Reagents, Kits, Instrument, Software), Test Type (Lab, POC), Disease (COVID-19, Flu, HAIs, HIV, HPV), Technology (Immunodiagnostics, NGS, INAAT, PCR), End User (Hospitals, Labs) - Global Forecast to 2027

感染症診断の世界市場規模は、2022年の355億ドルから2027年には331億ドルに達し、CAGRは-1.4%と予測されています。市場は、感染症の兆候、POC検査の増加傾向、技術的進歩などの要因によって牽引されています。し... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2022年6月11日	US$4,950 シングルユーザライセンスライセンス・価格情報・注文方法はこちら	287	215	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

感染症診断の世界市場規模は、2022年の355億ドルから2027年には331億ドルに達し、CAGRは-1.4%と予測されています。市場は、感染症の兆候、POC検査の増加傾向、技術的進歩などの要因によって牽引されています。しかし、償還条件が厳しいため、今後数年間は市場の成長がある程度限定されると予想されます。
「感染症診断薬市場において、試薬・キット・消耗品は、製品・サービス別で予測期間中に最大の市場シェアを占めた。
感染症診断薬市場は、試薬・キット・消耗品、機器、ソフトウェア・サービスに区分されます。2021年の感染症診断薬市場では、試薬・キット・消耗品セグメントが最大の市場シェアを占めています。このセグメントの成長を促す主な要因としては、感染症診断検査の実施件数の増加、より信頼性が高く、より特異的で、より早い段階での感染症検出の必要性の高まりが挙げられます。本製品は、感染症診断薬市場において、最大かつ最も成長率の高い製品セグメントです。また、試薬・キットを頻繁に必要とすることから、リカレントコストとなっています。
"蚊が媒介する疾患セグメントが最も高いCAGRを占めた"
感染症診断薬市場は、疾患タイプに基づき、COVID-19、HIV、院内感染、肝炎、クラミジアトラコマティス、ナイセリア淋病、HPV、結核、インフルエンザ、梅毒、蚊媒介性疾患、その他の感染症に区分される。2021年には、蚊が媒介する感染症セグメントが最も高いCAGRを占めています。
"Diagnostic Laboratoriessegmentが最大の市場シェアを占めた"
感染症診断市場は、エンドユーザーに基づき、診断ラボ、病院・診療所、学術研究機関、その他のエンドユーザーに区分されます。2021年の市場シェアは、診断ラボ部門が最も大きなシェアを占めています。これは、感染症診断における複雑で高度に専門化した検査の開発や、効率的な病気の診断と治療のための医療インフラの強化が要因であると考えられる。
本レポートのために実施した一次インタビューは、以下のように分類される。

- 企業タイプ別企業タイプ別：Tier1 40%、Tier2 30%、Tier3 30
- 役職別Cレベル：27％、Dレベル：18％、その他：55
- 地域別地域別：北米51％、欧州21％、アジア太平洋18％、中南米6％、中近東・アフリカ4
報告書に掲載されている企業名
- アボット・ラボラトリーズ（米国）
- F. ホフマン・ラ・ロシュ社（スイス(スイス)
- ビオメリューSA（フランス）
- サーモフィッシャーサイエンティフィック社（米国）
- ダナハーコーポレーション(米)
- QuidelCorporation（米国）
- ホロジック社(米国)
- パーキンエルマー社(米)
- バイオ・ラッド・ラボラトリーズ, Inc.(米)
- QIAGEN (オランダ)
- シーメンス・ヘルヒネアーズAG(ドイツ)
- ベクトン・ディッキンソンアンドカンパニー（米国）
- DiaSorin S.p.A(イタリア)
- Grifols S.A.（スペイン）
- シスメックス株式会社（日本）
- Seegene Inc.（韓国）
- オルソ・クリニカル・ダイアグノスティックス（米国）
- ジェネティック・シグネチャーズ（オーストラリア）
- メリディアン・バイオサイエンス（米国）
- オラシュア・テクノロジーズ（米国）
- トリニティ・バイオテック社（アイルランド） Trinity Biotech Plc.(アイルランド)
- チェンバイオ・ダイアグノスティック・システムズ（米国）
- コ・ダイアグノスティックス（米国）
- ELITechGroup（フランス）
- エピトープ・ダイアグノスティックス（米国）
- トリビットロンヘルスケア（インド）
- メリルライフサイエンス社（インド）Meril Life Sciences Pvt.(インド)
- インビオス・インターナショナル（米国）
- Uniogen Oy（フィンランド）
- ヴェラ・ダイアグノスティックス（シンガポール）
調査対象
本レポートは、世界の感染症診断薬市場の詳細な情報を提供します。製品・サービス、検査方法、技術、疾患タイプ、エンドユーザー、地域などの異なるセグメントにおける市場規模および将来の成長可能性を推定することを目的としています。また、主要な市場プレイヤーの会社概要、最近の開発状況、主要な市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主な利点
本レポートは、感染症診断薬市場全体とそのサブセグメントにおける収益数の概算を提供することで、市場リーダーや新規参入者を支援します。また、利害関係者が競争環境をより良く理解し、自社のビジネスをより良く位置づけ、適切な市場参入戦略を立てるためのより多くの洞察を得るのに役立ちます。本レポートは、関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供することを可能にします。

ページTOPに戻る

1 INTRODUCTION 32
1.1 STUDY OBJECTIVES 32
1.2 MARKET DEFINITION 32
1.2.1 INCLUSIONS AND EXCLUSIONS 33
1.3 MARKETS SCOPE 33
1.3.1 MARKETS COVERED 33
FIGURE 1 INFECTIOUS DISEASE DIAGNOSTICS MARKET SEGMENTATION 33
FIGURE 2 MARKETS COVERED - BY REGION 34
1.3.2 INFECTIOUS DISEASE DIAGNOSTICS MARKET: YEARS CONSIDERED 34
FIGURE 3 YEARS CONSIDERED 34
1.4 CURRENCY 35
1.5 LIMITATIONS 35
1.6 STAKEHOLDERS 35
1.7 SUMMARY OF CHANGES 36
2 RESEARCH METHODOLOGY 37
2.1 RESEARCH DATA 37
2.2 RESEARCH APPROACH 37
FIGURE 4 INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY 37
2.2.1 SECONDARY DATA 38
2.2.1.1 Key data from secondary sources 38
2.2.1.2 Secondary research activities 39
2.2.2 PRIMARY DATA 39
2.2.2.1 Primary sources 40
2.2.2.2 Key data from primary sources 41
2.2.2.3 Key industry insights 42
2.2.2.4 Breakdown of primary interviews 42
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS 42
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 43
2.3 MARKET SIZE ESTIMATION 43
2.3.1 BOTTOM-UP APPROACH 44
2.3.1.1 Approach 1: Company revenue estimation approach 44
FIGURE 7 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 44
2.3.1.2 Approach 2: Presentations of companies and primary interviews 44
2.3.1.3 Growth forecast 44
2.3.1.4 CAGR projections 45
FIGURE 8 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS 45
2.3.2 TOP-DOWN APPROACH 45
FIGURE 9 INFECTIOUS DISEASE DIAGNOSTICS MARKET: TOP-DOWN APPROACH 45
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 47
FIGURE 10 DATA TRIANGULATION METHODOLOGY 47
2.5 MARKET SHARE 48
2.6 STUDY ASSUMPTIONS 48
2.7 LIMITATIONS 49
2.8 GROWTH RATE ASSUMPTIONS 49
2.9 RISK ASSESSMENT 49
2.9.1 RISK ASSESSMENT: INFECTIOUS DISEASE DIAGNOSTICS MARKET 49
3 EXECUTIVE SUMMARY 50
FIGURE 11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION) 50
FIGURE 12 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022 VS. 2027 (USD MILLION) 51
FIGURE 13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,
2022 VS. 2027 (USD MILLION) 51
FIGURE 14 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,
2022 VS. 2027 (USD MILLION) 52
FIGURE 15 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION,
2022 VS. 2027 (USD MILLION) 52
4 PREMIUM INSIGHTS 54
4.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET OVERVIEW 54
FIGURE 16 RISING ADOPTION OF POC DIAGNOSTICS TO SUPPORT MARKET GROWTH DURING FORECAST PERIOD 54
4.2 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2022 VS. 2027 (USD MILLION) 55
FIGURE 17 REAGENTS, KITS, AND CONSUMABLES SEGMENT TO COMMAND LARGEST MARKET SHARE BY PRODUCT & SERVICE IN 2022 55
4.3 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022 VS. 2027 (USD MILLION) 55
FIGURE 18 IMMUNODIAGNOSTICS TO DOMINATE MARKET DURING FORECAST PERIOD 55
4.4 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2022 VS. 2027 56
FIGURE 19 DIAGNOSTIC LABORATORIES TO DOMINATE END USER MARKET 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS 57
FIGURE 20 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 57
5.2.1 DRIVERS 58
5.2.1.1 Global prevalence of infectious diseases 58
5.2.1.2 Rising focus on R&D and funding in infectious disease diagnostics 58
5.2.1.3 Growing awareness for early disease diagnosis in developing countries 59
5.2.1.4 Rising technological advancements in infectious disease diagnostics 60
5.2.1.5 Shift in focus from centralized laboratories to decentralized
POC testing 60
5.2.2 RESTRAINTS 61
5.2.2.1 Unfavorable reimbursement scenario 61
5.2.3 OPPORTUNITIES 61
5.2.3.1 Growth opportunities in growing economies 61
5.2.4 CHALLENGES 62
5.2.4.1 Changing regulatory landscape 62
5.2.4.2 Operational barriers 62
5.2.5 IMPACT OF COVID-19 ON INFECTIOUS DISEASE DIAGNOSTICS MARKET 62
5.3 PRICING ANALYSIS 64
5.3.1 INDICATIVE PRICING MODEL ANALYSIS 64
TABLE 1 INDICATIVE PRICE OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (2022) 64
5.4 PATENT ANALYSIS 65
FIGURE 21 LIST OF MAJOR PATENTS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES 65
5.4.1 LIST OF MAJOR PATENTS 66
5.5 VALUE CHAIN ANALYSIS 66
FIGURE 22 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 67
5.6 SUPPLY CHAIN ANALYSIS 67
FIGURE 23 INFECTIOUS DISEASE DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 68
5.7 ECOSYSTEM MARKET MAP 68
FIGURE 24 INFECTIOUS DISEASE DIAGNOSTICS MARKET: ECOSYSTEM MARKET MAP 69
5.7.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM 69
5.8 PORTER’S FIVE FORCES ANALYSIS 70
TABLE 2 INFECTIOUS DISEASE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 70
5.8.1 THREAT FROM NEW ENTRANTS 70
5.8.2 THREAT FROM SUBSTITUTES 70
5.8.3 BARGAINING POWER OF BUYERS 70
5.8.4 BARGAINING POWER OF SUPPLIERS 70
5.8.5 DEGREE OF COMPETITION 71
5.9 PESTLE ANALYSIS 71
5.10 REGULATORY LANDSCAPE 72
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72
TABLE 3 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72
TABLE 4 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72
TABLE 5 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73
TABLE 6 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73
5.10.2 NORTH AMERICA 73
5.10.2.1 US 73
5.10.2.2 Canada 73
5.10.3 EUROPE 74
TABLE 7 EUROPE: CLASSIFICATION OF DEVICES 74
5.10.4 ASIA PACIFIC 74
5.10.4.1 China 74
5.10.4.2 Japan 74
5.10.4.3 India 75
5.10.5 LATIN AMERICA 75
5.10.5.1 Brazil 75
5.10.5.2 Mexico 75
5.10.6 MIDDLE EAST 76
5.10.7 AFRICA 76
5.11 TRADE ANALYSIS 76
5.11.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 76
TABLE 8 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (USD MILLION) 76
TABLE 9 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (USD MILLION) 77
5.12 TECHNOLOGY ANALYSIS 77
5.13 KEY CONFERENCES & EVENTS IN 2022–2023 78
TABLE 10 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS 78
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 80
5.14.1 REVENUE SOURCES TO SHIFT TOWARD TECHNOLOGY-BASED SOLUTIONS DUE TO COVID-19 80
5.14.2 REVENUE TO SHIFT IN INFECTIOUS DISEASE DIAGNOSTICS MARKET 80
5.15 KEY STAKEHOLDERS & BUYING CRITERIA 81
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 81
FIGURE 25 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS 81
TABLE 11 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (%) 81
5.15.2 BUYING CRITERIA 82
FIGURE 26 KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS 82
TABLE 12 KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS 82
5.16 CASE STUDY 83
FIGURE 27 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING
BEHAVIOUR IN INDIA 83
6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 84
6.1 INTRODUCTION 85
TABLE 13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 85
TABLE 14 PRICES OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (2021) 85
6.2 REAGENTS, KITS, AND CONSUMABLES 86
6.2.1 RECURRENT PURCHASES OF REAGENTS, KITS, AND CONSUMABLES TO PROPEL MARKET GROWTH 86
TABLE 15 INFECTIOUS DISEASE DIAGNOSTIC REAGENTS, KITS, AND CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION) 87
6.3 INSTRUMENTS 87
6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST INSTRUMENTS DEMAND 87
TABLE 16 KEY INSTRUMENTS AVAILABLE IN MARKET 88
TABLE 17 INFECTIOUS DISEASE DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION) 89
6.4 SOFTWARE & SERVICES 89
6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE
SEGMENT GROWTH 89
TABLE 18 INFECTIOUS DISEASE DIAGNOSTIC SOFTWARE & SERVICES MARKET,
BY REGION, 2020–2027 (USD MILLION) 90
7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING 91
7.1 INTRODUCTION 92
TABLE 19 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING,
2020–2027 (USD MILLION) 92
7.2 LABORATORY TESTING 92
7.2.1 RISING INCIDENCE OF VARIOUS INFECTIOUS DISEASES TO DRIVE
MARKET GROWTH 92
TABLE 20 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING,
BY REGION, 2020–2027 (USD MILLION) 93
7.3 POC TESTING 93
7.3.1 INCREASING ADOPTION OF POC TECHNOLOGIES TO DRIVE SEGMENT GROWTH 93
TABLE 21 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY REGION, 2020–2027 (USD MILLION) 94
7.3.2 GLOBAL POC TESTING MARKET, BY END USER 94
TABLE 22 GLOBAL POC TESTING MARKET FOR INFECTIOUS DISEASES, BY END USER, 2020–2027 (USD MILLION) 94
TABLE 23 GLOBAL TESTS ADMINISTERED BY HEALTH PROFESSIONALS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION) 95
TABLE 24 GLOBAL CONSUMER SELF-TESTING MARKET FOR INFECTIOUS DISEASES,
BY REGION, 2020–2027 (USD MILLION) 95
TABLE 25 US: POC TESTING MARKET FOR INFECTIOUS DISEASES, BY END USER, 2020–2027 (USD MILLION) 95

7.3.3 POC TESTING MARKET FOR INFECTIOUS DISEASES BY POINT OF PURCHASE AND POINT OF RESULT 96
TABLE 26 US: POC TESTING MARKET FOR INFECTIOUS DISEASES, BY POINT OF PURCHASE AND POINT OF RESULT, 2020-2027 (USD MILLION) 96
8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY 97
8.1 INTRODUCTION 98
8.2 PRIMARY NOTES 98
8.2.1 KEY INDUSTRY INSIGHTS 98
TABLE 27 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION) 98
8.3 IMMUNODIAGNOSTICS 99
8.3.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND DEMAND FOR RAPID DIAGNOSTIC KITS TO DRIVE MARKET GROWTH 99
TABLE 28 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS,
BY REGION, 2020–2027 (USD MILLION) 99
8.3.2 IMMUNODIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY TYPE 100
TABLE 29 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION) 100
8.4 PCR 100
8.4.1 EMERGENCE OF ADVANCED TECHNOLOGIES SUCH AS QRT-PCR TO SUPPORT MARKET GROWTH 100
TABLE 30 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2020–2027 (USD MILLION) 101
8.5 CLINICAL MICROBIOLOGY 101
8.5.1 GROWING ADOPTION BY RESEARCHERS AND ACADEMIA TO DRIVE
MARKET GROWTH 101
TABLE 31 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY REGION, 2020–2027 (USD MILLION) 102
8.6 INAAT 102
8.6.1 COST BENEFITS OF INAAT TO DRIVE MARKET GROWTH 102
TABLE 32 MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2020–2027 (USD MILLION) 103
8.7 DNA SEQUENCING & NGS 103
8.7.1 INCREASING USE OF NGS IN CANCER DIAGNOSIS TO FUEL MARKET GROWTH 103
TABLE 33 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2020–2027 (USD MILLION) 104
8.8 DNA MICROARRAY 104
8.8.1 GROWING AWARENESS ABOUT ADVANCED TECHNOLOGIES TO DRIVE MARKET GROWTH 104
TABLE 34 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAY,
BY REGION, 2020–2027 (USD MILLION) 105
8.9 OTHER TECHNOLOGIES 105
TABLE 35 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES,
BY REGION, 2020–2027 (USD MILLION) 105

9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE 106
9.1 INTRODUCTION 107
TABLE 36 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 107
9.2 COVID-19 107
9.2.1 OUTBREAK OF COVID-19 PANDEMIC TO DOMINATE MARKET SHARE 107
TABLE 37 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2020–2027 (USD MILLION) 108
TABLE 38 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2020–2027 (MILLION TESTS) 108
TABLE 39 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR COVID-19, BY METHOD, 2020–2027 (USD MILLION) 109
9.3 HEPATITIS 109
9.3.1 INCREASING ADOPTION OF ADVANCED TECHNOLOGIES FOR HEPATITIS B DIAGNOSIS TO DRIVE SEGMENT GROWTH 109
TABLE 40 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2020–2027 (USD MILLION) 110
TABLE 41 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2020–2027 (MILLION TESTS) 110
TABLE 42 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY METHOD, 2020–2027 (USD MILLION) 110
9.4 HIV 111
9.4.1 HIGH GLOBAL PREVALENCE TO DRIVE SEGMENT GROWTH 111
TABLE 43 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY REGION,
2020–2027 (USD MILLION) 111
TABLE 44 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY REGION,
2020–2027 (MILLION TESTS) 112
9.5 HOSPITAL-ACQUIRED INFECTIONS 112
9.5.1 RISING BURDEN OF MRSA INFECTIONS TO DRIVE SEGMENT GROWTH 112
TABLE 45 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HAIS, BY REGION,
2020–2027 (USD MILLION) 113
TABLE 46 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HAIS, BY REGION,
2020–2027 (MILLION TESTS) 113
9.6 MOSQUITO-BORNE DISEASES 113
9.6.1 INCREASING INCIDENCE OF DENGUE TO DRIVE MARKET GROWTH 113
TABLE 47 MAJOR PRODUCTS: DENGUE TESTING 114
TABLE 48 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY REGION, 2020–2027 (USD MILLION) 115
9.7 HPV 115
9.7.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH 115
TABLE 49 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY REGION,
2020–2027 (USD MILLION) 116
TABLE 50 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY REGION,
2020–2027 (MILLION TESTS) 116

9.8 CHLAMYDIA TRACHOMATIS 116
9.8.1 GROWING INCIDENCE OF CHLAMYDIA AND RISING AWARENESS AMONG PATIENTS TO DRIVE MARKET GROWTH 116
TABLE 51 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CT, BY REGION,
2020–2027 (USD MILLION) 117
TABLE 52 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CT, BY REGION,
2020–2027 (MILLION TESTS) 117
9.9 NEISSERIA GONORRHEA 118
9.9.1 RISING INCIDENCE OF GONORRHEA AND GROWING FUNDING FOR R&D TO DRIVE MARKET GROWTH 118
TABLE 53 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NG, BY REGION,
2020–2027 (USD MILLION) 118
9.10 TUBERCULOSIS 118
9.10.1 INCREASING BURDEN OF TUBERCULOSIS GLOBALLY TO DRIVE MARKET GROWTH 118
TABLE 54 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS,
BY REGION, 2020–2027 (USD MILLION) 119
TABLE 55 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS,
BY REGION, 2020–2027 (MILLION TESTS) 119
TABLE 56 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS,
BY METHOD, 2020–2027 (USD MILLION) 120
9.11 INFLUENZA 120
9.11.1 RISING FOCUS ON CONTROLLING INFLUENZA TO DRIVE MARKET GROWTH 120
TABLE 57 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2020–2027 (USD MILLION) 121
TABLE 58 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2020–2027 (MILLION TESTS) 121
TABLE 59 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY METHOD, 2020–2027 (USD MILLION) 121
9.12 SYPHILIS 122
9.12.1 GROWING ADOPTION OF NOVEL TECHNOLOGIES TO SUPPORT MARKET GROWTH 122
TABLE 60 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY REGION, 2020–2027 (USD MILLION) 122
9.13 OTHER INFECTIOUS DISEASES 122
TABLE 61 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION) 123
10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER 124
10.1 INTRODUCTION 125
TABLE 62 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION) 125
10.2 DIAGNOSTIC LABORATORIES 125
10.2.1 INCREASING OUTSOURCING TO DIAGNOSTIC LABORATORIES FOR REDUCED COSTS TO LED TO LARGEST MARKET SHARE 125
TABLE 63 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 126
10.3 HOSPITALS & CLINICS 126
10.3.1 INCREASING ADOPTION OF DIAGNOSTIC TOOLS TO SUPPORT MARKET GROWTH 126
TABLE 64 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS,
BY REGION, 2020–2027 (USD MILLION) 127
10.4 ACADEMIC RESEARCH INSTITUTES 127
10.4.1 FOCUS ON DEVELOPING INNOVATIVE TESTS TO DRIVE MARKET GROWTH 127
TABLE 65 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 128
10.5 OTHER END USERS 128
TABLE 66 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS,
BY REGION, 2020–2027 (USD MILLION) 129
11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION 130
11.1 INTRODUCTION 131
TABLE 67 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION,
2020–2027 (USD MILLION) 131
11.2 NORTH AMERICA 131
FIGURE 28 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT 132
TABLE 68 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 133
TABLE 69 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 133
TABLE 70 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2020–2027 (USD MILLION) 133
TABLE 71 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY DISEASE TYPE, 2020–2027 (USD MILLION) 134
TABLE 72 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY END USER, 2020–2027 (USD MILLION) 134
11.2.1 US 135
11.2.1.1 Increasing prevalence of infectious diseases to drive market growth 135
TABLE 73 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 135
TABLE 74 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION) 136
TABLE 75 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 136
TABLE 76 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION) 137
11.2.2 CANADA 137
11.2.2.1 Focus on affordable tests to drive market growth 137
TABLE 77 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 137
TABLE 78 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 138
TABLE 79 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 138
TABLE 80 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 139
11.3 EUROPE 139
TABLE 81 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 140
TABLE 82 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 140
TABLE 83 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 141
TABLE 84 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 141
TABLE 85 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 142
11.3.1 GERMANY 142
11.3.1.1 Increasing healthcare expenditure to drive market growth 142
TABLE 86 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 143
TABLE 87 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 143
TABLE 88 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 144
TABLE 89 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 144
11.3.2 UK 145
11.3.2.1 Growing number of accredited diagnostic laboratories to propel market growth 145
TABLE 90 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 145
TABLE 91 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION) 146
TABLE 92 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 146
TABLE 93 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION) 147
11.3.3 FRANCE 147
11.3.3.1 Rising R&D expenditure and increasing demand for early diagnosis to drive market growth 147
TABLE 94 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 147
TABLE 95 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 148
TABLE 96 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 148
TABLE 97 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 149

11.3.4 ITALY 149
11.3.4.1 Adoption of advanced diagnostic technologies to drive market growth 149
TABLE 98 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 150
TABLE 99 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 150
TABLE 100 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 151
TABLE 101 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION) 151
11.3.5 SPAIN 152
11.3.5.1 Rising geriatric population to drive market growth 152
TABLE 102 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 152
TABLE 103 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 153
TABLE 104 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 153
TABLE 105 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION) 154
11.3.6 REST OF EUROPE 154
TABLE 106 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 154
TABLE 107 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2020–2027 (USD MILLION) 155
TABLE 108 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 155
TABLE 109 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY END USER, 2020–2027 (USD MILLION) 156
11.4 ASIA PACIFIC 156
FIGURE 29 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT 157
TABLE 110 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 157
TABLE 111 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 158
TABLE 112 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2020–2027 (USD MILLION) 158
TABLE 113 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 159
TABLE 114 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 159
11.4.1 CHINA 160
11.4.1.1 Growing public access to modern healthcare to drive market growth 160
TABLE 115 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 160
TABLE 116 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 161
TABLE 117 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 161
TABLE 118 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 162
11.4.2 JAPAN 162
11.4.2.1 Universal healthcare reimbursement policy to drive market growth 162
TABLE 119 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 163
TABLE 120 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 163
TABLE 121 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 164
TABLE 122 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION) 164
11.4.3 INDIA 165
11.4.3.1 Increasing private & public investments in healthcare system to drive market growth 165
TABLE 123 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 165
TABLE 124 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 166
TABLE 125 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 166
TABLE 126 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION) 167
11.4.4 REST OF ASIA PACIFIC 167
TABLE 127 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 167
TABLE 128 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2020–2027 (USD MILLION) 168
TABLE 129 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY DISEASE TYPE, 2020–2027 (USD MILLION) 168
TABLE 130 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY END USER, 2020–2027 (USD MILLION) 169
11.5 LATIN AMERICA 169
11.5.1 RISING DISEASE PREVALENCE AND HEALTHCARE EXPENDITURE TO DRAW FOREIGN PLAYERS 169
TABLE 131 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 170
TABLE 132 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2020–2027 (USD MILLION) 170
TABLE 133 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 171
TABLE 134 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 171

11.6 MIDDLE EAST & AFRICA 172
11.6.1 RISING ACCESS TO ADVANCED TECHNOLOGIES AND GROWING INVESTMENTS TO SUPPORT MARKET GROWTH 172
TABLE 135 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 172
TABLE 136 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2020–2027 (USD MILLION) 173
TABLE 137 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY DISEASE TYPE, 2020–2027 (USD MILLION) 173
TABLE 138 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET,
BY END USER, 2020–2027 (USD MILLION) 174
12 COMPETITIVE LANDSCAPE 175
12.1 OVERVIEW 175
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 175
12.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS 175
TABLE 139 OVERVIEW OF STRATEGIES DEPLOYED BY KEY INFECTIOUS DISEASE DIAGNOSTIC MANUFACTURING COMPANIES 175
12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 177
FIGURE 30 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET 177
12.4 MARKET SHARE ANALYSIS 178
12.4.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET 178
FIGURE 31 INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2021) 178
TABLE 140 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DEGREE OF COMPETITION 178
12.5 COMPANY EVALUATION QUADRANT 179
12.5.1 LIST OF EVALUATED VENDORS 179
12.5.2 STARS 179
12.5.3 EMERGING LEADERS 179
12.5.4 PERVASIVE PLAYERS 180
12.5.5 PARTICIPANTS 180
FIGURE 32 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021 180
12.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/ SMES (2021) 181
12.6.1 PROGRESSIVE COMPANIES 181
12.6.2 STARTING BLOCKS 181
12.6.3 RESPONSIVE COMPANIES 181
12.6.4 DYNAMIC COMPANIES 181
FIGURE 33 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021 182
12.7 COMPETITIVE BENCHMARKING 183
12.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS 183
FIGURE 34 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET 183
TABLE 141 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS 183
TABLE 142 COMPANY PRODUCT & SERVICE FOOTPRINT 184
TABLE 143 COMPANY REGIONAL FOOTPRINT 184
TABLE 144 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES 185
12.8 COMPETITIVE SCENARIO 185
12.8.1 PRODUCT LAUNCHES 185
TABLE 145 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS 185
12.8.2 DEALS 186
TABLE 146 KEY DEALS 186
13 COMPANY PROFILES 187
(Business overview, Products offered, Recent Developments, MNM view)*
13.1 KEY PLAYERS 187
13.1.1 ABBOTT LABORATORIES 187
TABLE 147 ABBOTT LABORATORIES: BUSINESS OVERVIEW 187
FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021) 188
TABLE 148 PRODUCT LAUNCHES & APPROVALS 191
13.1.2 F. HOFFMANN-LA ROCHE LTD. 193
TABLE 149 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 193
FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021) 194
13.1.3 THERMO FISHER SCIENTIFIC INC. 199
TABLE 150 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 199
FIGURE 37 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021) 200
13.1.4 SIEMENS HEALTHINEERS AG 204
TABLE 151 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW 204
FIGURE 38 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021) 205
13.1.5 BIOMÉRIEUX SA 209
TABLE 152 BIOMÉRIEUX SA: BUSINESS OVERVIEW 209
FIGURE 39 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2021) 210
13.1.6 DANAHER CORPORATION 215
TABLE 153 DANAHER CORPORATION: BUSINESS OVERVIEW 215
FIGURE 40 DANAHER CORPORATION: COMPANY SNAPSHOT (2021) 216
13.1.7 HOLOGIC, INC. 220
TABLE 154 HOLOGIC, INC.: BUSINESS OVERVIEW 220
FIGURE 41 HOLOGIC, INC.: COMPANY SNAPSHOT (2021) 221
13.1.8 BECTON, DICKINSON AND COMPANY 224
TABLE 155 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 224
FIGURE 42 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021) 225
13.1.9 PERKINELMER, INC. 230
TABLE 156 PERKINELMER, INC.: BUSINESS OVERVIEW 230
FIGURE 43 PERKINELMER, INC.: COMPANY SNAPSHOT (2021) 231
13.1.10 SEEGENE, INC. 235
TABLE 157 SEEGENE, INC.: BUSINESS OVERVIEW 235
FIGURE 44 SEEGENE, INC.: COMPANY SNAPSHOT (2021) 236
13.1.11 QUIDEL CORPORATION 240
TABLE 158 QUIDEL CORPORATION: BUSINESS OVERVIEW 240
FIGURE 45 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021) 240
13.1.12 QIAGEN N.V. 245
TABLE 159 QIAGEN N.V.: BUSINESS OVERVIEW 245
FIGURE 46 QIAGEN N.V.: COMPANY SNAPSHOT (2021) 246
13.1.13 DIASORIN S.P.A 250
TABLE 160 DIASORIN S.P.A: BUSINESS OVERVIEW 250
FIGURE 47 DIASORIN S.P.A: COMPANY SNAPSHOT (2021) 251
13.1.14 BIO-RAD LABORATORIES, INC. 258
TABLE 161 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 258
FIGURE 48 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2021) 259
13.1.15 GRIFOLS S.A. 263
TABLE 162 GRIFOLS S.A.: BUSINESS OVERVIEW 263
FIGURE 49 GRIFOLS S.A.: COMPANY SNAPSHOT (2021) 264
13.1.16 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC 266
TABLE 163 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: BUSINESS OVERVIEW 266
FIGURE 50 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: COMPANY
SNAPSHOT (2021) 267
13.1.17 SYSMEX CORPORATION 270
TABLE 164 SYSMEX CORPORATION: BUSINESS OVERVIEW 270
FIGURE 51 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021) 270
13.2 OTHER PLAYERS 272
13.2.1 MERIDIAN BIOSCIENCE 272
13.2.2 ORASURE TECHNOLOGIES 274
13.2.3 CO-DIAGNOSTICS 275
13.2.4 CHEMBIO DIAGNOSTIC SYSTEMS 276
13.2.5 TRINITY BIOTECH PLC 277
13.2.6 GENETIC SIGNATURES LTD. 278
13.2.7 EPITOPE DIAGNOSTICS 279
13.2.8 TRIVITRON HEALTHCARE 280
13.2.9 ELITECHGROUP 281
13.2.10 MERIL LIFESCIENCES PVT. LTD. 283
13.2.11 INBIOS INTERNATIONAL 283
13.2.12 UNIOGEN OY 285
13.2.13 VELA DIAGNOSTICS 285
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
14 APPENDIX 287
14.1 DISCUSSION GUIDE 287
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 291
14.3 AVAILABLE CUSTOMIZATIONS 293
14.4 RELATED REPORTS 293
14.5 AUTHOR DETAILS 294

ページTOPに戻る

Table of Contents

Summary

The global infectious disease diagnostics market size is projected to reach USD 33.1 billion by 2027 from USD 35.5 billion in 2022, at a -1.4% CAGR.Market is driven by factors such as indication of infectious diseases, growing trend in POC testing and rising technological advancements. However,an unfavorable reimbursement scenario is expected to limit market growth to a certain extent in the forecasted years.
“The reagents, kits, and consumablesaccounted for the largest market sharein theinfectious disease diagnostics market, byproduct& service, during the forecast period”
The infectious disease diagnostics market is segmented into reagents, kits, and consumables; instruments; and software & services. The reagents, kits, and consumables segment accounted for the largest market share in the infectious disease diagnostics market in 2021. Major factors driving the growth of this segment include the increasing number of infectious disease diagnostic tests carried out, the growing need for more reliable, more specific, and faster detection of infectious diseases in the early stages. This is the largest and fastest-growing product segment in the infectious disease diagnostics market. Also, the frequent need for reagents & kits makes it a recurrent cost.
“Mosquito-borne diseasessegment accounted for the highest CAGR”
Based on the disease type, the infectious disease diagnostics market is segmented into COVID-19, HIV, Hospital-acquired infections, hepatitis, Chlamydia trachomatis, Neisseria Gonorrhea, HPV, Tuberculosis, influenza, syphilis, mosquito-borne diseases and other infectious diseases. In 2021, the mosquito-borne diseasessegment accounted for the highest CAGR.
“Diagnostic Laboratoriessegment accounted for the largest market share”
Based on end-users, the infectious disease diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, academic research institutes, and other end users. The diagnostic laboratories segment accounted for the largest market share in 2021. This can be attributed to the development of complex and highly specialized tests in infectious disease diagnostics and strengthening healthcare infrastructures for efficient disease diagnosis and treatment.
The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 - 40%, Tier 2 - 30%,and Tier 3 -30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America -51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and the Middle East & Africa – 4%
Lits of Companies Profiled in the Report:
• Abbott Laboratories (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• bioMérieux SA (France)
• Thermo Fisher Scientific Inc. (US)
• Danaher Corporation (US)
• QuidelCorporation(US)
• Hologic, Inc. (US)
• PerkinElmer Inc. (US)
• Bio-Rad Laboratories, Inc. (US)
• QIAGEN (Netherlands)
• Siemens Healthineers AG (Germany)
• Becton, Dickinson and Company (US)
• DiaSorin S.p.A (Italy)
• Grifols S.A. (Spain)
• Sysmex Corporation (Japan)
• Seegene Inc. (South Korea)
• Ortho Clinical Diagnostics (US)
• Genetic Signatures (Australia)
• Meridian Bioscience (US)
• OraSure Technologies (US)
• Trinity Biotech Plc. (Ireland)
• Chembio Diagnostic Systems (US)
• Co-Diagnostics (US)
• ELITechGroup (France)
• Epitope Diagnostics (US)
• Trivitron Healthcare (India)
• Meril Life Sciences Pvt. Ltd. (India)
• InBios International (US)
• Uniogen Oy (Finland)
• Vela Diagnostics (Singapore)
Research Coverage:
This report provides a detailed picture of the global infectious disease diagnostics market. It aims at estimating the size and future growth potential of the market across different segments, such as product& service, test of testing, technology,disease type, end user, and region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall infectious disease diagnostics market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（診断薬）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（covid19）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（診断薬）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（covid19）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?